Grifols (NASDAQ:GRFS) Lowered to "Buy" Rating by Wall Street Zen

Key Points

• The stock analysts at Wall Street Zen downgraded Grifols (NASDAQ:GRFS) from a "strong-buy" to a "buy" rating in their latest report.
• Grifols currently has an average rating of "Moderate Buy" with a price target of $10.30, according to MarketBeat.
• Several hedge funds have recently increased or acquired new stakes in Grifols, indicating growing institutional interest in the company.

Grifols (NASDAQ:GRFS - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research report issued to clients and investors on Saturday.

Several other equities research analysts have also recently weighed in on GRFS. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Grifols in a research note on Tuesday, August 5th. Zacks Research raised Grifols to a "hold" rating in a research note on Friday, August 8th. JPMorgan Chase & Co. increased their price target on Grifols from $7.60 to $10.30 and gave the company a "neutral" rating in a research note on Tuesday, June 17th. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of Grifols in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, Grifols currently has an average rating of "Moderate Buy" and an average price target of $10.30.

Grifols Price Performance

Shares of GRFS opened at $9.32 on Friday. Grifols has a 12-month low of $6.19 and a 12-month high of $11.14. The business has a 50-day simple moving average of $10.02 and a two-hundred day simple moving average of $8.88. The company has a quick ratio of 0.95, a current ratio of 2.64 and a debt-to-equity ratio of 1.20. The stock has a market cap of $6.41 billion, a PE ratio of 7.97, a PEG ratio of 0.32 and a beta of 0.69.

Institutional Investors Weigh In On Grifols

Hedge funds have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC increased its holdings in Grifols by 127.4% in the second quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company's stock worth $74,000 after purchasing an additional 4,604 shares in the last quarter. Ballentine Partners LLC acquired a new stake in Grifols in the first quarter valued at approximately $77,000. R Squared Ltd acquired a new stake in Grifols in the second quarter valued at approximately $95,000. Ameriprise Financial Inc. acquired a new stake in Grifols in the second quarter valued at approximately $95,000. Finally, Bessemer Group Inc. grew its stake in Grifols by 1,693.8% in the second quarter. Bessemer Group Inc. now owns 11,821 shares of the biotechnology company's stock valued at $107,000 after acquiring an additional 11,162 shares during the period.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.